FOLFIRINOX: A small step or a great leap forward?

Journal of Clinical Oncology

Volumn 29, Issue 28, 2011, Pages 3727-3729

  Ko, Andrew H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PLACEBO;

ADVERSE OUTCOME; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL RESEARCH; DIARRHEA; FEBRILE NEUTROPENIA; HUMAN; MONOTHERAPY; NEUTROPENIA; NOTE; PANCREAS CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SENSORY NEUROPATHY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS;

EID: 80053592994     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.3464     Document Type: Note

References (12)

1. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007 (Pubitemid 46972777)
2. Heinemann V, Boeck S, Hinke A, et al: Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8:82, 2008
3. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
4. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
5. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
6. Artinyan A, Soriano PA, Prendergast C, et al: The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford) 10:371-376, 2008
7. Cunningham D, Chau I, Stocken DD, et al: Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513-5518, 2009
8. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005
9. Haller DG, Cassidy J, Clarke SJ, et al: Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26:2118-2123, 2008
10. Sanoff HK, Sargent DJ, Green EM, et al: Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: A subgroup analysis of a large randomized clinical trial. J Clin Oncol 27:4109-4115, 2009
11. Boeck S, Hoehler T, Seipelt G, et al: Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): Final results of a multicenter randomized phase II trial in advanced pancreatic cancer. Ann Oncol 19:340-347, 2008 (Pubitemid 351201717)
12. Pelzer U, Kubica K, Stieler J, et al: A randomized trial in patients with gemcitabine refractory pancreatic cancer: Final results of the CONKO 003 study. J Clin Oncol 26:215s, 2008 (suppl; abstr 4508)